

Supporting Information for:

The weaker-binding Fc γ receptor IIIa F158 allotype retains sensitivity to N-glycan composition and exhibits a destabilized antibody-binding interface


Paul G. Kremer¹ and Adam W. Barb^{1,2,3}

Supplemental Table 1. N162 glycan composition of CD16a expressed in HEK293F cells


Allotype	Glycan	MS2	z	Calc (M+zH) ^{z+}	Obs (M+zH) ^{z+}	Intensity (arb)	RT	PPM error	Mass error (Da)	Peptide
F	HexNAc(5)Hex(5)Fuc(1)	X	3	927.0392	927.0381	2500	9	1.230	0.00114	GSKNVSE
F	HexNAc(5)Hex(4)Fuc(1)	X	3	873.0216	873.0211	5300	9	0.607	0.00053	GSKNVSE
F	HexNAc(5)Hex(3)Fuc(1)	X	3	819.0040	819.0026	2500	9	1.734	0.00142	GSKNVSE
V	HexNAc(5)Hex(5)Fuc(1)	X	3	960.0620	960.0625	103000	11	-0.479	0.00046	VGSKNVSE
V	HexNAc(5)Hex(4)Fuc(1)	X	3	906.0444	906.0444	377000	11	0.033	3E-05	VGSKNVSE
V	HexNAc(5)Hex(3)Fuc(1)	X	3	852.0268	852.0268	182000	11	0.023	2E-05	VGSKNVSE
V	HexNAc(4)Hex(3)Fuc(1)	X	3	784.3337	784.3337	240000	10	0.000	0	VGSKNVSE
V	HexNAc(2)Hex(5)	X	3	870.3758	870.3763	117000	15	-0.574	0.0005	CRGLVGSKNVSE
V	HexNAc(6)Hex(3)Fuc(1)	X	3	919.7200	919.7196	220000	10	0.381	0.00035	VGSKNVSE
V	HexNAc(3)Hex(3)Fuc(1)	X	2	1074.4572	1074.4572	150000	10	0.019	2E-05	VGSKNVSE
V	HexNAc(4)Hex(5)Fuc(1)	X	3	892.3689	892.3685	296000	10	0.471	0.00042	VGSKNVSE
V	HexNAc(4)Hex(4)Fuc(1)	X	3	838.3513	838.3509	215000	10	0.489	0.00041	VGSKNVSE
V	HexNAc(5)Hex(6)Fuc(1)	X	3	1014.0797	1014.0799	100000	9	-0.247	0.00025	VGSKNVSE

Supplemental Table 2. CD16a affinities relative to the complex-type glycoform


	Complex-type	Man5	(1)GlcNAc	S164A
V158	1.0	3.4	13	1.1
F158	1.0	1.6	13	1.1





Supplemental Figure 1. SDS-PAGE of GFP-srCD16a fusions. The two different allotypes are expressed with four different glycosylation patterns. Distinct shifts in migration are observed between each type of glycosylated protein.



Supplemental Figure 2. Relative abundance of N162 glycans on the V158 and F158 allotypes as determined by glycoproteomics MS. The N162-containing glycopeptide for F158 provides less intense peaks by ESI-MS/MS as our lab previously noted (Mol Cell Proteomics. 2019 Nov;18(11):2178-2190; Mol Cell Proteomics. 2020 Feb;19(2):362-374). Possible N-glycan configurations are shown as cartoons below the chart.



Supplemental Figure 3. Representative surface plasmon resonance (SPR) sensorgrams of CD16a allotypes with either Man5 oligomannose N-glycans (A,E) or (1)GlcNAc N-glycans (C,G). Fits of the dissociation constants and associated errors from equilibrium binding measurements are also shown (B,D,F,H). Cartoons show the expected N-glycan at the N162 site.




Supplemental Figure 4. **(A)** Overlay of HSQC-TROSY spectra of CD16a V158 with (black) and without (green) the N162 glycan. Residues with large chemical shift perturbations are bolded. **(B)** Highlighted peaks showing differences between the V158, V158/S164A and F158 spectra.

Supplemental Figure 5. Assigned N162 glycopeptide MS2 spectra (following pages)

L.VGSKN[+1810]VSSE.T z=3,scan#=2528,scan time=11.1943


MS2 V158 #1



MS2 V158 #2




Intensity



MS2 V158 #3




Intensity



MS2 V158 #4




Intensity



MS2 V158 #5




Intensity



MS2 V158 #6




Intensity



MS2 V158 #7




Intensity




MS2 V158 #8




Intensity



MS2 V158 #9



MS2 V158 #10





V.GSKN[+1810]VSSE.T z=3,scan#=1725,scan time=8.7152

MS2 F158 #1



Intensity





MS2 F158 #3



Intensity

